| The announcement was made during market hours today, 28 February 2017. Meanwhile, the S&P BSE Sensex was up 10.86 points or 0.04% at 28,823.74. On the BSE, 31,000 shares were traded on the counter so far as against the average daily volumes of 71,954 shares in the past one quarter. The stock had hit a high of Rs 1,477.50 and a low of Rs 1,461.25 so far during the day. The stock had hit a 52-week high of Rs 1,874.30 on 14 March 2016 and a 52-week low of Rs 1,294.05 on 29 March 2016. It had underperformed the market over the past one month till 27 February 2017, sliding 1.86% compared with the Sensex's 3.34% rise. The scrip had also underperformed the market over the past one quarter, declining 3.01% as against the Sensex's 9.49% rise. The large-cap company has equity capital of Rs 90.31 crore. Face value per share is Rs 2. Lupin said it has received final approval from the United States Food and Drug Administration (USFDA) for its Sodium Sulfate, Potassium Sulfate, and Magnesium Sulfate Oral Solution, 17.5g/3.13g/1.6g per 6 ounces to market a generic version of Braintree Laboratories' Suprep Bowel Prep Kit. Lupin shall commence promoting the product shortly. Braintree Laboratories' Suprep Bowel Prep Kit is indicated for cleansing of the colon in preparation for colonoscopy in adults. Suprep Bowel Prep Kit had annual US sales of $207.2 million as per IMS MAT December 2016 data. Lupin's consolidated net profit rose 20.7% to Rs 633.11 crore on 31.5% increase in net sales to Rs 4404.94 crore in Q3 December 2016 over Q3 December 2015. Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The company is a significant player in the cardiovascular, diabetology, asthma, pediatric, CNS, GI, anti-infective and NSAID space and holds global leadership position in the anti-TB segment. Powered by Capital Market - Live News |